Because GUAIFENESIN has no more patent protection, being an old generic medication and an over-the-counter drug, no pharmaceutical company will bear the expense (evaluated at $ 800 M) of a large clinical double-blind trials necessary for FDA approval of GUAIFENESIN’s new use for fibromyalgia (it is an already FDA-approved medication since 1952 as expectorant).
Besides the above, one should be interested to think over what is featured on the cover of Lancet Volume 366 Number 9480, July 9-15, 2005: “If everything has to be double-blinded, randomized, and evidence-base, where does that leave new ideas?”
PREGNANCY and FIBROMYALGIA
Dr. Kurland Norbert If you have fibromyalgia and are contemplating pregnancy, it’s natural to wonder what impact your illness will have on your ability to